Gerti Tashko, MD
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1669688024
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,172 of the $106,318 with a category attached, or 77.3%. Novo Nordisk accounts for 90.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $49,833 and has fallen 99.8% since, to $115 in 2025. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $478.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$96K
- Corcept Therapeutics$9K
- Dexcom, Inc.$115
- Abbott$106
- Amarin Pharma, Inc.$94
- Lilly USA, LLC$67
- plus $421 from 16 others
What the payments were for
- Consulting fees$6,5006%
- Speaking & faculty fees$82,17277%
- Travel & lodging$13,76813%
- Food & beverage$3,8764%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 142 | $96,082 |
| Corcept Therapeutics | 34 | $9,433 |
| Dexcom, Inc. | 1 | $115 |
| Abbott | 6 | $106 |
| Amarin Pharma, Inc. | 6 | $94 |
| Lilly USA, LLC | 4 | $67 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Amneal Pharmaceuticals LLC | 3 | $46 |
| Insulet Corporation | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| AbbVie | 2 | $36 |
| IBSA Pharma Inc. | 2 | $32 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Boehringer Ingelheim | 2 | $26 |
| Radius Health, Inc. | 2 | $25 |
| AstraZeneca | 1 | $21 |
| Mannkind Corporation | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Amgen | 1 | $14 |
| Medtronic | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$44,623
- RYBELSUS$27,849
- Tresiba$19,354
- Korlym$8,769
- DEXCOM G7 GSS (161)$115
- DEXCOM STELO GLUCOSE BIOSENSOR$115
How this compares
$106,318 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $152,905 |
| OzempicSemaglutide | 45 | $81,435 |
| JardianceEmpagliflozin | 16 | $25,915 |
| FarxigaDapagliflozin Propanediol | 15 | $20,647 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $14,107 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,993 |
| SynthroidLevothyroxine Sodium | 15 | $1,677 |
| Rosuvastatin Calcium | 65 | $1,228 |
| Testosterone Cypionate | 13 | $707 |
| Ezetimibe | 20 | $658 |
| Glimepiride | 36 | $571 |
| Lisinopril | 17 | $427 |
| Omega-3 Acid Ethyl Esters | 13 | $285 |
| Amlodipine Besylate | 18 | $281 |
| Metformin Hcl | 46 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $67 | $152,90579 claims |
| Novo NordiskOzempic | $96,082 | $81,43545 claims |
| Boehringer IngelheimJardiance | $26 | $25,91516 claims |
| AstraZenecaFarxiga | $21 | $20,64715 claims |
| AbbVieSynthroid | $36 | $1,67715 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $46 | $25428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- David BrownRockville$497K
- Helena RodbardRockville$468K
- Jie HeRockville$26K
- Monika MannanRockville$8K
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- Philip LevinBaltimore$489K
- Roy PhillipsBel Air$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.